These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 21840277)

  • 21. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.
    Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S
    Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
    Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using the Pharmaceutical Collection Database to identify patient adherence to oral hypoglycaemic medicines.
    Kharjul MD; Cameron C; Braund R
    J Prim Health Care; 2019 Sep; 11(3):265-274. PubMed ID: 32171380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fixed-dose combination therapies in the management of hyperglycaemia in Type 2 diabetes: an opportunity to improve adherence and patient care.
    Schernthaner G
    Diabet Med; 2010 Jul; 27(7):739-43. PubMed ID: 20636953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased risk of affective disorders in type 2 diabetes is minimized by sulfonylurea and metformin combination: a population-based cohort study.
    Wahlqvist ML; Lee MS; Chuang SY; Hsu CC; Tsai HN; Yu SH; Chang HY
    BMC Med; 2012 Nov; 10():150. PubMed ID: 23194378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SMS reminders improve adherence to oral medication in type 2 diabetes patients who are real time electronically monitored.
    Vervloet M; van Dijk L; Santen-Reestman J; van Vlijmen B; van Wingerden P; Bouvy ML; de Bakker DH
    Int J Med Inform; 2012 Sep; 81(9):594-604. PubMed ID: 22652012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
    Berkowitz SA; Krumme AA; Avorn J; Brennan T; Matlin OS; Spettell CM; Pezalla EJ; Brill G; Shrank WH; Choudhry NK
    JAMA Intern Med; 2014 Dec; 174(12):1955-62. PubMed ID: 25347323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discrepancies among consensus documents, guidelines, clinical practice and the legal framework for the treatment of type 2 diabetes mellitus patients.
    del Pozo-Fernández C; Pardo-Ruiz C; Sánchez-Botella C; Blanes-Castañer V; López-Menchero R; Gisbert-Sellés C; Sánchez-Jodar C; Alvarez-Avellán L
    Nefrologia; 2012 May; 32(3):367-73. PubMed ID: 22592422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline.
    Bramlage P; Binz C; Gitt AK; Krekler M; Plate T; Deeg E; Tschöpe D
    Cardiovasc Diabetol; 2010 Sep; 9():53. PubMed ID: 20843379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multistate model and an algorithm for measuring long-term adherence to medication: a case of diabetes mellitus type 2.
    Jensen ML; Jørgensen ME; Hansen EH; Aagaard L; Carstensen B
    Value Health; 2014 Mar; 17(2):266-74. PubMed ID: 24636386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interrogation of a longitudinal, national pharmacy claims dataset to explore factors that predict the need for add-on therapy in older and socioeconomically disadvantaged Australians with type 2 diabetes mellitus patients (T2DM).
    Kumar SS; McManus H; Radovich T; Greenfield JR; Viardot A; Williams KM; Cronin P; Day RO
    Eur J Clin Pharmacol; 2018 Oct; 74(10):1327-1332. PubMed ID: 29938343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
    Janka HU; Plewe G; Riddle MC; Kliebe-Frisch C; Schweitzer MA; Yki-Järvinen H
    Diabetes Care; 2005 Feb; 28(2):254-9. PubMed ID: 15677775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial.
    Azar ST; Echtay A; Wan Bebakar WM; Al Araj S; Berrah A; Omar M; Mutha A; Tornøe K; Kaltoft MS; Shehadeh N
    Diabetes Obes Metab; 2016 Oct; 18(10):1025-33. PubMed ID: 27376711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications.
    Desai NR; Shrank WH; Fischer MA; Avorn J; Liberman JN; Schneeweiss S; Pakes J; Brennan TA; Choudhry NK
    Am J Med; 2012 Mar; 125(3):302.e1-7. PubMed ID: 22340932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharma-clinics. Medication of the month. Glimepiride (Amarylle)].
    Scheen AJ
    Rev Med Liege; 2000 Mar; 55(3):184-6. PubMed ID: 10823010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discontinuation of statins among patients with type 2 diabetes.
    Lamberts EJ; Nijpels G; Welschen LM; Hugtenburg JG; Dekker JM; Souverein PC; Bouvy ML
    Diabetes Metab Res Rev; 2012 Mar; 28(3):241-5. PubMed ID: 21898755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guideline-conformity of initiation with oral hypoglycemic treatment for patients with newly therapy-dependent type 2 diabetes mellitus in Austria.
    Winkelmayer WC; Stedman MR; Pogantsch M; Wieninger P; Bucsics A; Asslaber M; Bauer R; Burkhardt T; Schautzer A; Brookhart MA;
    Pharmacoepidemiol Drug Saf; 2011 Jan; 20(1):57-65. PubMed ID: 21182153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact].
    Sicras-Mainar A; Navarro-Artieda R
    Rev Peru Med Exp Salud Publica; 2014; 31(4):626-34. PubMed ID: 25597711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. National trends in metformin-based combination therapy of oral hypoglycaemic agents for type 2 diabetes mellitus.
    Kim J; Park S; Kim H; Je NK
    Eur J Clin Pharmacol; 2019 Dec; 75(12):1723-1730. PubMed ID: 31475315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.